Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
This article was originally published in The Pink Sheet Daily
The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.
You may also be interested in...
Stockwatch: Gilead, BMS Expose High Cost Of M&A
Expensive acquisitions are in the spotlight during earnings season. The purchases of Kite and Celgene by Gilead and Bristol-Myers Squibb are not turning out to be what was written on the tin.
The Cost Of A Cure: Gilead Exec Outlines Factors In Sovaldi’s Pricing
Gilead Science Executive VP Gregg Alton defended Sovaldi’s pricing at an AEI event July 11, the same day Senators Wyden and Grassley sent a letter requesting detailed information on the company’s investment in the drug and how it set the price.
It’s “Full Speed Ahead” For Merck In HCV After $3.85B Idenix Buyout
The company expects to come charging out of the gate with a three-drug combo therapy for hepatitis C now that it has acquired a nucleotide analog to round out its portfolio. Merck is undeterred by the risks associated with the deal.